Abstract

180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
Celestine S Tung ... Kwong-Kwok Wong
Modern Pathology | VOL. 22
Celestine S Tung, et. al.Celestine S Tung ... Kwong-Kwok Wong
01 Sep 2009
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis
Robert J Kurman ... Ie-Ming Shih
American Journal of Obstetrics and Gynecology | VOL. 198
Robert J Kurman, et. al.Robert J Kurman ... Ie-Ming Shih
01 Apr 2008
High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the \u201cSET\u201d feature of high-grade serous carcinoma to the \u201cSTEM\u201d feature
Yuichiro Hatano ... Akira Hara
Diagnostic Pathology | VOL. 14
Yuichiro Hatano, et. al.Yuichiro Hatano ... Akira Hara
12 Jan 2019
Cell Proliferation in Ovarian Carcinoma: Superior Accuracy of S-Phase Fraction (SPF) by DNA Labeling Index versus Flow Cytometric SPF, Lack of Independent Prognostic Power for SPF and DNA Ploidy, and Limited Effect of SPF on Tumor Growth Rate
John S Meyer ... Stephen Yim
Gynecologic oncology | VOL. 81
John S Meyer, et. al.John S Meyer ... Stephen Yim
01 Jun 2001
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Integrated non-invasive diagnostics for prediction of survival in immunotherapy
Melda Yeghaian ... Stefano Trebeschi
Immuno-Oncology and Technology | VOL. -
Melda Yeghaian, et. al.Melda Yeghaian ... Stefano Trebeschi
01 Jul 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 22
--
01 Jun 2024
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
Isabella A.J Van Duin ... Karijn P.M Suijkerbuijk
Immuno-Oncology and Technology | VOL. -
Isabella A.J Van Duin, et. al.Isabella A.J Van Duin ... Karijn P.M Suijkerbuijk
01 Jun 2024
Regional and intratumoral adoptive T-cell therapy
Irene Olivera ... Ignacio Melero
Immuno-Oncology and Technology | VOL. -
Irene Olivera, et. al.Irene Olivera ... Ignacio Melero
01 Jun 2024
View more papers